Immix Biopharma moved quickly after an interim readout from its Phase II NEXICART-2 trial for BCMA-targeted CAR-T NXC-201 in light-chain (AL) amyloidosis. Days of investor attention intensified when the company announced a $125 million offering shortly after reporting an 89% complete response rate among 45 patients with interim data. The follow-on financing—underwritten by J.P. Morgan—signals that Immix intends to sustain operations and prepare regulatory activities, with management indicating a planned BLA submission next year and final study data expected to close out NEXICART-2. For the sector, the pairing of strong interim efficacy with rapid capital raises highlights demand for new CAR-T constructs in amyloidosis as developers try to secure timelines toward approval.